-
Part 1 | Session 2 View from the Thoraxcenter: ESC 21 Late-breaking Science Wrap Up
-
Part 2 | Session 1 ESC 2021 Discussion: The EMPEROR-Preserved Trial
-
Part 2 | Session 2 ESC 2021 Discussion: The FIGARO-DKD Trial
-
Part 2 | Session 3 ESC 2021 Discussion: The EMPEROR-Pooled Study
-
Part 3 | Session 2 SYNTAX II Trial: 5yr Data Shows Reduction in MACE in PCI
-
Part 3 | Session 3 TWILIGHT-HBR: Ticagrelor Monotherapy in HBR Patients Undergoing PCI
-
Part 3 | Session 4 The LAAOS III Study: Surgical AFIB Ablation Evaluation
-
Part 3 | Session 5 TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type
-
Part 3 | Session 6 STOPDAPT-2 ACT: 1-Month DAPT Followed by Clopidogrel Monotherapy in ACS
-
Part 3 | Session 7 SPLENDOR: Metabolic Surgery and Risk of MACE in NASH
-
Part 3 | Session 9 VOYAGER PAD: Rivaroxaban in Symptomatic PAD With & Without Comorbid Diabetes
-
Part 3 | Session 10 Micra CED: 2-Year Outcomes with Leadless Pacing
-
Part 3 | Session 11 RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes
Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data.
For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviewed principal investigators on their studies, learnings, and applicability to clinical practice in her regular Late-Breaker Discussion Series.
Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Part 1
View from the Thoraxcenter
Part 2
Late-breaker Discussion Series
Part 3
Expert Interviews
Part 4
Masterclass with Dr Harriette Van Spall & Dr Birgit Vogel
Faculty Biographies
Nicolas M Van Mieghem
Medical Director
Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors.
His current research focuses on cerebral embolic protection during TAVI and the search for improved large bore closure devices. He works actively in expanding TAVI indications, most notably TAVI as a means to further unload the left ventricle in heart failure patients with moderate aortic stenosis (the TAVR UNLOAD trial). Prof Van Mieghem is also involved in the development and dispersion of mechanical circulatory support (MCS) devices as well as transcatheter mitral…
Joost Daemen
Interventional Cardiologist
Dr Joost Daemen, MD, PhD is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center, Rotterdam in 2005 and did 2 years of internal medicine training and 4 years of general cardiology training at the Thoraxcenter, Rotterdam.
Dr Daemen is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.